Dessislava Marinova

1.8k total citations
27 papers, 1.2k citations indexed

About

Dessislava Marinova is a scholar working on Infectious Diseases, Immunology and Epidemiology. According to data from OpenAlex, Dessislava Marinova has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 23 papers in Immunology and 9 papers in Epidemiology. Recurrent topics in Dessislava Marinova's work include Tuberculosis Research and Epidemiology (24 papers), Immune responses and vaccinations (15 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Dessislava Marinova is often cited by papers focused on Tuberculosis Research and Epidemiology (24 papers), Immune responses and vaccinations (15 papers) and Immunodeficiency and Autoimmune Disorders (9 papers). Dessislava Marinova collaborates with scholars based in Spain, France and Netherlands. Dessislava Marinova's co-authors include Carlos Martı́n, Nacho Aguiló, Jesús Gonzalo‐Asensio, Santiago Uranga, Marta Monzón, Juan José Badiola, Julián Pardo, Samuel Álvarez-Arguedas, Ainhoa Arbués and Eugenia Puentes and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Dessislava Marinova

27 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dessislava Marinova Spain 18 977 784 434 226 100 27 1.2k
Santiago Uranga Spain 14 716 0.7× 577 0.7× 355 0.8× 191 0.8× 102 1.0× 26 943
Bernard Landry United Kingdom 11 963 1.0× 712 0.9× 556 1.3× 199 0.9× 145 1.4× 16 1.2k
Alissa C. Rothchild United States 17 955 1.0× 891 1.1× 590 1.4× 451 2.0× 123 1.2× 26 1.8k
Asma Ahmed India 17 362 0.4× 427 0.5× 264 0.6× 249 1.1× 66 0.7× 51 898
Lise Brandt United States 8 1000 1.0× 686 0.9× 572 1.3× 258 1.1× 140 1.4× 9 1.1k
Ainhoa Arbués France 16 769 0.8× 352 0.4× 508 1.2× 260 1.2× 143 1.4× 25 943
Azra Blazevic United States 13 524 0.5× 845 1.1× 507 1.2× 156 0.7× 69 0.7× 26 1.2k
Joshua S. Woodworth United States 19 960 1.0× 873 1.1× 599 1.4× 330 1.5× 111 1.1× 22 1.4k
Margaret Ann Snowden South Africa 5 676 0.7× 520 0.7× 348 0.8× 145 0.6× 85 0.8× 6 824
Graham Hatch United Kingdom 14 642 0.7× 381 0.5× 517 1.2× 333 1.5× 82 0.8× 22 951

Countries citing papers authored by Dessislava Marinova

Since Specialization
Citations

This map shows the geographic impact of Dessislava Marinova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dessislava Marinova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dessislava Marinova more than expected).

Fields of papers citing papers by Dessislava Marinova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dessislava Marinova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dessislava Marinova. The network helps show where Dessislava Marinova may publish in the future.

Co-authorship network of co-authors of Dessislava Marinova

This figure shows the co-authorship network connecting the top 25 collaborators of Dessislava Marinova. A scholar is included among the top collaborators of Dessislava Marinova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dessislava Marinova. Dessislava Marinova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marinova, Dessislava, et al.. (2023). A rare variation of superior rectus muscle. SHILAP Revista de lepidopterología. 65(3). 514–517. 1 indexed citations
2.
Dijkman, Karin, Nacho Aguiló, Charelle Boot, et al.. (2021). Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Reports Medicine. 2(1). 100187–100187. 33 indexed citations
3.
Uranga, Santiago, Ana Belén Gómez, Dessislava Marinova, et al.. (2021). Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment. EBioMedicine. 64. 103186–103186. 7 indexed citations
4.
Martı́n, Carlos, Dessislava Marinova, Nacho Aguiló, & Jesús Gonzalo‐Asensio. (2021). MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG. Vaccine. 39(50). 7277–7285. 41 indexed citations
5.
Aguiló, Nacho, Santiago Uranga, Ana Belén Gómez, et al.. (2020). Respiratory Immunization With a Whole Cell Inactivated Vaccine Induces Functional Mucosal Immunoglobulins Against Tuberculosis in Mice and Non-human Primates. Frontiers in Microbiology. 11. 1339–1339. 13 indexed citations
6.
Marinova, Dessislava, et al.. (2019). Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines. Nature Communications. 10(1). 5457–5457. 3 indexed citations
7.
Iglesias, María José, Sofía Samper, Dessislava Marinova, et al.. (2018). Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures. Proceedings of the National Academy of Sciences. 115(14). 26 indexed citations
8.
Clark, Simon, et al.. (2017). Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis. The Journal of Infectious Diseases. 216(5). 525–533. 33 indexed citations
9.
Gonzalo‐Asensio, Jesús, Dessislava Marinova, Carlos Martı́n, & Nacho Aguiló. (2017). MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. Frontiers in Immunology. 8. 1803–1803. 66 indexed citations
10.
Aguiló, Nacho, Jesús Gonzalo‐Asensio, Samuel Álvarez-Arguedas, et al.. (2017). Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nature Communications. 8(1). 16085–16085. 93 indexed citations
11.
Sanz, Joaquín, et al.. (2016). On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines. PeerJ. 4. e1513–e1513. 14 indexed citations
12.
Uranga, Santiago, Dessislava Marinova, Carlos Martı́n, Julián Pardo, & Nacho Aguiló. (2016). Granzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo. PLoS ONE. 11(4). e0153028–e0153028. 9 indexed citations
13.
Uranga, Santiago, Dessislava Marinova, Carlos Martı́n, & Nacho Aguiló. (2016). Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice. Journal of Visualized Experiments. 13 indexed citations
14.
Aguiló, Nacho, Santiago Uranga, Dessislava Marinova, et al.. (2015). MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis. 96. 71–74. 51 indexed citations
15.
Aguiló, Nacho, Samuel Álvarez-Arguedas, Santiago Uranga, et al.. (2015). Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17–Dependent Mechanism. The Journal of Infectious Diseases. 213(5). 831–839. 101 indexed citations
16.
Spertini, François, R Audran, Anne‐Christine Thierry, et al.. (2015). Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. The Lancet Respiratory Medicine. 3(12). 953–962. 126 indexed citations
17.
Arbués, Ainhoa, Nacho Aguiló, Jesús Gonzalo‐Asensio, et al.. (2013). Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 31(42). 4867–4873. 190 indexed citations
18.
Aguiló, Nacho, Dessislava Marinova, Carlos Martı́n, & Julián Pardo. (2013). ESX-1-induced apoptosis during mycobacterial infection: to be or not to be, that is the question. Frontiers in Cellular and Infection Microbiology. 3. 88–88. 40 indexed citations
19.
Marinova, Dessislava, Jesús Gonzalo‐Asensio, Nacho Aguiló, & Carlos Martı́n. (2013). Recent developments in tuberculosis vaccines. Expert Review of Vaccines. 12(12). 1431–1448. 29 indexed citations
20.
Arbués, Ainhoa, Nacho Aguiló, Marta Monzón, et al.. (2012). Attenuated Mycobacterium tuberculosis SO2 Vaccine Candidate Is Unable to Induce Cell Death. PLoS ONE. 7(9). e45213–e45213. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Santiago Uranga Breakdown of academic impact, for papers by Bernard Landry Breakdown of academic impact, for papers by Alissa C. Rothchild Breakdown of academic impact, for papers by Asma Ahmed Breakdown of academic impact, for papers by Lise Brandt Breakdown of academic impact, for papers by Ainhoa Arbués Breakdown of academic impact, for papers by Azra Blazevic Breakdown of academic impact, for papers by Joshua S. Woodworth Breakdown of academic impact, for papers by Margaret Ann Snowden Breakdown of academic impact, for papers by Graham Hatch
Rankless by CCL
2026